Skip to content
Bomb Report – Lifestyle
Author:
Organogenesis Holdings Inc.
Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee Osteoarthritis
July 6, 2026
Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results
May 7, 2026
Organogenesis Completes Rolling Submission of Biologics License Application for ReNu®
April 28, 2026
Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM
April 7, 2026
Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain
April 7, 2026
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026
April 6, 2026